SCHEMBL4674355

SCHEMBL4674355

O=C(O)/C(O)=C/C(=O)c1cc[nH]c1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
AKR1C3 P42330 1/20 0.36
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
MITF O75030 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
CASP6 P55212 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MMP1 P03956 2/20 0.33
MMP2 P08253 2/20 0.33
MMP9 P14780 2/20 0.33
MMP13 P45452 2/20 0.33
MMP3 P08254 1/20 0.33
MMP12 P39900 1/20 0.33
MMP14 P50281 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674359 1.00 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4679604 0.87 HTR6 (0.37) MAPTMEN1ALDH1A1LMNAHTT
SCHEMBL4679610 0.87 HTR6 (0.37) MAPTMEN1ALDH1A1LMNAHTT
SCHEMBL4672968 0.86 ALDH1A1 (0.40) AKR1C2AKR1C1AKR1C3MAPTMEN1
SCHEMBL4672962 0.86 ALDH1A1 (0.40) AKR1C2AKR1C1AKR1C3MAPTMEN1
SCHEMBL4676854 0.80 MMP1 (0.38) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4676852 0.80 MMP1 (0.38) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4671304 0.78 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4671306 0.78 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4672202 0.78 MMP1 (0.39) PTGS2AKR1C2AKR1C1AKR1C3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGS2 4586/4885AKR1C2 24/4885AKR1C1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.